# PanSeer

Source: https://onco.cc/drugs/panseer/  
OnCo record `panseer` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Singlera's methylation blood test, tested on stored samples from a Chinese cohort, that reported finding cancers up to four years before they were diagnosed; it has not been confirmed in a prospective study.

## Summary

In Chen et al. (Nature Communications 2020), PanSeer was run on stored plasma from the Taizhou Longitudinal Study (123,115 healthy people who gave samples): among 605 asymptomatic people, 191 later diagnosed with stomach, oesophageal, colorectal, lung or liver cancer within four years, it detected cancer in 95% of those later diagnosed, and in 88% of post-diagnosis patients at 96% specificity. The authors state that future longitudinal studies are required to confirm the result. Singlera's website no longer lists PanSeer or another multi-cancer product (it lists single-cancer colorectal and liver tests); its FuSion (NCT05159544) and INSPIRE (NCT06440018) studies develop multi-omic and methylation-plus-fragmentomics successors. No regulatory status was found.

## Fields

- Kind: Treatment
- Status: emerging
- Last checked: 2026-10-29
- Tags: test; mced; evidence:insufficient
- Brand: PanSeer
- Modality: Multi-cancer blood test (circulating tumour DNA methylation), research assay
- Mechanism: Targeted methylation sequencing of circulating tumour DNA for five common cancers.

## Notes

- Evidence grade insufficient for the claim that taking this test reduces late-stage diagnosis or cancer deaths: no randomised trial of it has reported either outcome, and its published performance comes from case-control or single-arm studies. The only randomised result for any multi-cancer test, NHS-Galleri, did not show fewer stage III or IV cancers.
- The four-years-early figure is from a small nested case-control analysis of stored samples, which tends to overstate screening performance.
- What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening).

## Sources

- Chen et al., Nature Communications 2020: https://doi.org/10.1038/s41467-020-17316-z

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- technologies: [Cell-free DNA methylation tests](https://onco.cc/technologies/cfdna-methylation-testing/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- companies: [Singlera Genomics](https://onco.cc/companies/singlera/)
- trials: [FuSion (Fudan and Singlera pan-cancer screening cohort)](https://onco.cc/trials/fusion-singlera/), [INSPIRE (Singlera methylation and fragmentomics case-control study)](https://onco.cc/trials/inspire-singlera/)
- key papers: [Non-invasive early detection of cancer four years before conventional diagnosis using a blood test](https://onco.cc/key-papers/paper-panseer-nat-commun-2020/)

---
JSON: https://onco.cc/api/v1/entities/panseer.json